A phase II study of temozolomide (TMZ) and pegylated interferon α-2b (PGI) in the treatment of advanced melanoma
Susan E. Krown(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Cornell University), Lynne Lamb(Memorial Sloan Kettering Cancer Center), Wen-Jen Hwu(The University of Texas MD Anderson Cancer Center), K. Panageas(Memorial Sloan Kettering Cancer Center), Suzan Aird(Memorial Sloan Kettering Cancer Center), Linda Williams(Edinburgh Cancer Research), P. B. Chapman(Memorial Sloan Kettering Cancer Center), P O Livingston(Memorial Sloan Kettering Cancer Center), Jennifer H. Menell
Cited by 0
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k